✦ LIBER ✦

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

✍ Scribed by Jagannath, Sundar; Vij, Ravi; Stewart, A. Keith; Trudel, Suzanne; Jakubowiak, Andrzej J.; Reiman, Tony; Somlo, George; Bahlis, Nizar; Lonial, Sagar; Kunkel, Lori A.; Wong, Alvin; Orlowski, Robert Z.; Siegel, David S.

Book ID: 122361926
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 400 KB
Volume: 12
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2012.08.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9236 Results of PX-171–003-A0, part 1 of

9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma

✍ Siegel, D.; Vij, R.; Stewart, K.; Somlo, G.; Jakubowiak, A.; Kukreti, V.; Bahlis 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

A377 Phase II Study of Carfilzomib in Pa

A377 Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)

✍ Jagannath, S; Vij, R; Stewart, AK; Somlo, G; Jakubowiak, A; Reiman, T; Trudel, S 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 85 KB

An open-label, single-arm, phase 2 study

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

✍ Ravi Vij; David S. Siegel; Sundar Jagannath; Andrzej J. Jakubowiak; Alexander Ke 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Design and rationale of FOCUS (PX-171-01

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

✍ Roman Hájek, Richard Bryce, Sunhee Ro, Barbara Klencke, Heinz Ludwig 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 167 KB

Efficacy and safety of melphalan, arseni

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study

✍ James R. Berenson; Ralph Boccia; David Siegel; Marek Bozdech; Alberto Bessudo; E 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 573 KB

An open-label, single-arm Phase II study

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

✍ Peter G. Rose; Bradley J. Monk; Diane Provencher; Jean Hartney; Philippe Legenne 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB